ARK Reports About 7% Of Absci — Its Stake Carries No Control Aim
ARK Genomic Revolution ETF was the only client with an interest above 5% in the reported shares.
ARK Investment Management reported about 7% of Absci, which uses AI and laboratory testing to develop antibody drugs, in a passive ownership disclosure filed Friday. The position covered September 30, and ARK certified that it held the shares for ordinary business purposes without seeking to change or influence company control.
One Position, Shared Reporting
ARK reported 11,928,917 common shares, equal to 6.95% of the class on the disclosure's beneficial-ownership basis. ARK Genomic Revolution ETF, a client of the investment manager, was the only client above the 5% interest threshold for those securities.
Catherine D. Wood, ARK's chief executive officer and chief investment officer, joined the disclosure as a reporting person. Her reported share count matched ARK's: both entries described the same position.
ARK reported sole authority to vote the shares and decide their disposal. Wood reported shared authority for both. The share counts therefore describe overlapping reporting authority, not separate holdings to add together.
The control certification covers both the purpose of holding the securities and participation in transactions aimed at changing or influencing control, with an exception for activities solely connected to a nomination under the specified SEC rule.
AI Drug Discovery And Owned Medicines
Absci develops medicines of its own and works on drug discovery with pharmaceutical and biotechnology partners, including Merck, AstraZeneca and Almirall. Its collaborations can produce upfront payments, research fees, milestone payments and royalties.
The company's lead drug candidate, ABS-201, is being developed for pattern hair loss and endometriosis. Clinical testing is underway for hair loss.
As of December 31, 2025, Absci was advancing five internally developed programs that it wholly owned, along with additional programs in early discovery. Its drug-creation platform uses combined laboratory space exceeding 77,000 square feet.
ARK's exchange-traded funds hold concentrated positions in small and midsize companies. Those holdings frequently cross reporting thresholds; ARK generated about 170 ownership schedules over two years.
Absci's market value was $1.6 billion in Friday trading as of 1:16 p.m. ET.
The reported ownership gives ARK voting and disposal authority over a substantial Absci position, while its certification places that holding outside an effort to change company control.
Sources
- SCHEDULE 13G/A — ARK Investment Management LLC re: Absci Corp (ABSI) — SEC EDGAR
- SCHEDULE 13G/A Exhibit 1 — EXHIBIT 1 — SEC EDGAR